[{"id":"db0a2604-60f8-4da8-9709-756a668e89e5","acronym":"","url":"https://clinicaltrials.gov/study/NCT01520558","created_at":"2021-01-18T06:23:46.768Z","updated_at":"2024-07-02T16:37:20.522Z","phase":"Phase 1/2","brief_title":"CNDO-109-AANK for AML in First Complete Remission (CR1)","source_id_and_acronym":"NCT01520558","lead_sponsor":"Coronado Biosciences, Inc.","biomarkers":" FLT3 • NPM1 • HLA-B","pipe":" | ","alterations":" FLT3 mutation • NPM1 mutation • Chr del(5q)","tags":["FLT3 • NPM1 • HLA-B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 mutation • NPM1 mutation • Chr del(5q)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CNDO-109"],"overall_status":"Unknown status","enrollment":" Enrollment 12","initiation":"Initiation: 12/01/2012","start_date":" 12/01/2012","primary_txt":" Primary completion: 03/01/2016","primary_completion_date":" 03/01/2016","study_txt":" Completion: 02/01/2018","study_completion_date":" 02/01/2018","last_update_posted":"2017-06-29"}]